The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)

Agents that have shown improvements in survival in mCRPC now include abiraterone, enzalutamide, docetaxel, cabazitaxel and radium-223. Bone supportive agents and palliative radiation continue to play an important role in the overall management of mCRPC. Given the complexity, variety and importance o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Can Urol Assoc J
Hauptverfasser: Saad, Fred, Chi, Kim N., Finelli, Antonio, Hotte, Sebastien J., Izawa, Jonathan, Kapoor, Anil, Kassouf, Wassim, Loblaw, Andrew, North, Scott, Rendon, Ricardo, So, Alan, Usmani, Nawaid, Vigneault, Eric, Fleshner, Neil E.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Canadian Medical Association 2015
Schlagworte:
CUA Guidelines
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4455631/
https://ncbi.nlm.nih.gov/pubmed/26085865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.2526
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge